Working… Menu

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LILAC™)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04279314
Recruitment Status : Enrolling by invitation
First Posted : February 21, 2020
Last Update Posted : September 5, 2021
Information provided by (Responsible Party):
ACADIA Pharmaceuticals Inc.

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022